Clinical Trial Update: IASO206 in Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) clinical trial of IASO206 for relapsed/refractory multiple myeloma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• IASO206

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory Multiple Myeloma (RRMM) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING